The low frequency of blood CD56dim CD16+ NK cells found in some EBV+ cHL patients might impair the clinical efficacy to the bi-specific anti-CD30/CD16A antibody construct AFM13 currently assessed in a phase 2 study of patients with refractory or relapsed cHL (NCT02321592). Here, FCGR3A is linked to classic Hodgkin lymphoma.